Rhein shows potent efficacy against non-small-cell lung cancer through inhibiting the STAT3 pathway

References

• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• YatabeYKerrKMUtomoAEGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic surveyJ Thorac Oncol201510343844525376513
   PubMed Web of Science ®Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• HirschFRScagliottiGVMulshineJLLung cancer: current therapies and new targeted treatmentsLancet20173891006629931127574741
   PubMed Web of Science ®Google Scholar
• YuHLeeHHerrmannABuettnerRJoveRRevisiting STAT3 signalling in cancer: new and unexpected biological functionsNat Rev Cancer2014141173674625342631
   PubMed Web of Science ®Google Scholar
• YuHPardollDJoveRSTATs in cancer inflammation and immunity: a leading role for STAT3Nat Rev Cancer200991179880919851315
   PubMed Web of Science ®Google Scholar
• ChunJLiRJChengMSKimYSAlantolactone selectively suppresses STAT3 activation and exhibits potent anticancer activity in MDA-MB-231 cellsCancer Lett2015357139340325434800
   PubMed Web of Science ®Google Scholar
• DevarajanEHuangSSTAT3 as a central regulator of tumor metastasesCurr Mol Med20099562663319601811
   PubMed Web of Science ®Google Scholar
• YuHJoveRThe STATs of cancer – new molecular targets come of ageNat Rev Cancer2004429710514964307
   PubMed Web of Science ®Google Scholar
• ZhangTLiSLiJNatural product pectolinarigenin inhibits osteo-sarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibitionCell Death Dis2016710e242127735939
   PubMedGoogle Scholar
• BaiEYangLXiangYL61H46 shows potent efficacy against human pancreatic cancer through inhibiting STAT3 pathwayCancer Manag Res20181056558129606890
   PubMed Web of Science ®Google Scholar
• ZhengHHongHZhangLNifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cellsCancer Manag Res2017956557229138596
   PubMed Web of Science ®Google Scholar
• CortasTEisenbergRFuPKernJPatrickLDowlatiAActivation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancerLung Cancer200755334935517161498
   PubMed Web of Science ®Google Scholar
• GaoSPMarkKGLeslieKMutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasJ Clin Invest2007117123846385618060032
   PubMed Web of Science ®Google Scholar
• HauraEBZhengZSongLCantorABeplerGActivated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancerClin Cancer Res200511238288829416322287
   PubMed Web of Science ®Google Scholar
• BarréBVigneronAPerkinsNRoninsonIBGamelinECoqueretOThe STAT3 oncogene as a predictive marker of drug resistanceTrends Mol Med200713141117118707
   PubMed Web of Science ®Google Scholar
• IkutaKTakemuraKKiharaMOverexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cellsOncol Rep200513221722215643501
   PubMed Web of Science ®Google Scholar
• YouSLiRParkDDisruption of STAT3 by niclosamide reverses radioresistance of human lung cancerMol Cancer Ther201413360661624362463
   PubMed Web of Science ®Google Scholar
• ZhongZWenZDarnellJEJrSTAT3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6Science1994264515595988140422
   PubMed Web of Science ®Google Scholar
• AlvarezJVGreulichHSellersWRMeyersonMFrankDASignal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptorCancer Res20066663162316816540667
   PubMed Web of Science ®Google Scholar
• ZhaoCLiHLinHJYangSLinJLiangGFeedback activation of STAT3 as a cancer drug-resistance mechanismTrends Pharmacol Sci2016371476126576830
   PubMed Web of Science ®Google Scholar
• LeeHJZhuangGCaoYDuPKimHJSettlemanJDrug resistance via feedback activation of STAT3 in oncogene-addicted cancer cellsCancer Cell201426220722125065853
   PubMed Web of Science ®Google Scholar
• Van SchaeybroeckSKalimuthoMDunnePDADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancerCell Rep2014761940195524931611
   PubMed Web of Science ®Google Scholar
• CostaDBNguyenKSChoBCEffects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinibClin Cancer Res200814217060706718981003
   PubMed Web of Science ®Google Scholar
• ZhouYXXiaWYueWPengCRahmanKZhangHRhein: a review of pharmacological activitiesEvid Based Complement Alternat Med201520151110
   Google Scholar
• DebordPLouchahiKTodMCournotAPerretGPetitjeanOInfluence of renal function on the pharmacokinetics of diacerein after a single oral doseEur J Drug Metab Pharmacokinet199419113197957446
   PubMed Web of Science ®Google Scholar
• JangWKimTKooJSKimSKLimDSMechanical cue-induced YAP instructs Skp2-dependent cell cycle exit and oncogenic signalingEMBO J201736172510252828673931
   PubMed Web of Science ®Google Scholar
• JiangRJinZLiuZSunLWangLLiKCorrelation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinomaMol Diagn Ther201115634735222208386
   PubMed Web of Science ®Google Scholar
• XuYHLuSXA meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancerEur J Surg Oncol201440331131724332948
   PubMed Web of Science ®Google Scholar
• BhartiRDeyGBanerjeeISomatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapyCancer Lett201738829230228025102
   PubMed Web of Science ®Google Scholar
• BhartiRDeyGOjhaPKDiacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancerOncogene201635303965397526616855
   PubMed Web of Science ®Google Scholar